The effect of prednisolone on the sensitivity of Technetium 99m-methylene diphosphonate ( 99m Tc-MDP) scintigraphy to detect simulated closed fracture in the rat tibia

Document Type: Original Article

Authors

1 Department of Medicinal Chemistry, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences Ahvaz, Iran

2 Department of Nuclear Medicine, Golestan Hospital, Ahvaz, Iran

3 Department of Pharmacology and Toxicology, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

4 Department of Pharmaceutics, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

5 School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Abstract

Introduction: The purpose of the present study was to evaluate the effect of prednisolone on the sensitivity of bone scanning to detect the simulated closed fracture in the rat tibia.
 Methods: A total number of forty eight adult, male NMRI rats randomly assigned into two parts, one part for 4 and other for 8 weeks experiments. Each part has been divided into four groups, one group not receiving prednisolone (control group) and the other groups receiving 5, 10 and 20 mg/kg prednisolone respectively. After four and eight weeks of experiments a simulated closed fracture was created in the tibia approximately 1 cm near knee joint. .The scintigraphy imaging has been performed on second and fifth day after tibial bone fracture and the ratio of the activity of tibia bone fracture to the contra lateral healthy side was calculated (R factor).
Results: All scintigraphy images showed the rat tibia bone fracture. Statistically significant difference in the R factors have been observed, when scintigraphy images were performed in fifth day after injury.
Conclusion: Bone radionuclide scanning by 99mTc-MDP is very sensitive for detection of occult fracture.  In order to enhance bone scan sensitivity, it may be reasonable to postpone 99mTc-MDP scintigraphy imaging at least 2 to 3 days after suspected trauma in patients receiving glucocorticoid medication.

Keywords

Main Subjects


Love C, Din AS, Tomas MB, Kalapparambath TP, Palestro CJ. Radionuclide bone imaging: an illustrative review. Radiographics. 2003 Mar-Apr;23(2):341-58.

Zuckier LS, Freeman LM. Nonosseous, nonurologic uptake on bone scintigraphy: atlas and analysis. Semin Nucl Med. 2010 Jul;40(4):242-56.

Galasko CS. The pathological basis for skeletal scintigraphy.  J Bone Joint Surg Br. 1975 Aug;57(3):353-9.

Genant HK, Bautovich GJ, Singh M, Lathrop KA, Harper PV. Bone-seeking radionuclides: an in vivo study of factors affecting skeletal uptake. Radiology. 1974 Nov;113(2):373-82.

Lin KH, Shih BF, Tsao CH, Wu MC. Diffuse liver uptake of Technetium-99m- MDP bone scan due to hepatotoxicity secondary to methotrexate therapy. Ann Nucl Med Sci. 2005;18:111-5.

Bernardo-Filho M, Santos-Filho SD, Moura EG, Maiworm AI, Camoes Orlando MM, Penas ME, Cardoso VN, Bernardo LC, Brito LC. Drug interaction with radiopharmaceutical: a review. Braz Arch Biol Technol. 2005;48:13-27.

Carvalho Xavier Holanda CM, Carvalho Holanda Leite R, Silva Nunes RA, Oliveira HA, Almeida Catanho MTJ, Souza  GML, Bernardo-Filho M. Effect of antimalarial drugs on the bioavailability of the methylenediphosphonic acid labeled with technetium99m (99mTc-MDP) in wistar rats.  Braz Arch Biol Technol. 2006;49(2):207-14.

Grover VK, Babu R, Bedi  SPS. Steroid therapy –current indications in practice.  Indian J Anaesth. 2007;51(5):389-93.

Ton FN, Gunawardene SC, Lee H, Neer RM. Effects of low-dose prednisone on bone metabolism. J Bone Miner Res. 2005 Mar;20(3):464-70.

Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology. 1999 Oct;140(10):4382-9.

Scott S, Alazraki N, Manaster B. Failure of bone scanning to detect fractures in a woman on chronic steroid therapy. Skeletal Radiol. 1984;12(3):204-7.

Scott SM, Manaster BJ, Alazraki N, Wooten WW, Murphy K. Technetium-99m imaging of bone trauma: reduced sensitivity caused by hydrocortisone in rabbits. AJR Am J Roentgenol. 1987 Jun;148(6):1175-8.

Ortoft G, Oxlund H. Reduced strength of rat cortical bone after glucocorticoid treatment.  Calcif Tissue Int. 1988 Dec;43(6):376-82.

Kondo N, Tokunaga K, Ito T, Arai K, Amizuka N, Minqi L, Kitahara H, Ito M, Naito M, Shu-Ying J, Oda K, Murai T, Takano R, Ogose A, Endo N. High dose glucocorticoid hampers bone formation and resorption after bone marrow ablation in rat. Microsc Res Tech. 2006 Oct;69(10):839-46.

Kozai Y, Kawamata R, Sakurai T, Kanno M, Kashima I. Influence of prednisolone-induced osteoporosis on bone mass and bone quality of the mandible in rats. Dentomaxillofac Radiol. 2009 Jan;38(1):34-41.

McLaughlin F, Mackintosh J, Hayes BP, McLaren A, Uings IJ, Salmon P, Humphreys J, Meldrum E, Farrow SN. Glucocorticoid-induced osteopenia in the mouse as assessed by histomorphometry, microcomputed tomography, and biochemical markers. Bone. 2002 Jun;30(6):924-30. 

Hara K, Akiyama Y, Ohkawa I, Tajima T. Effects of menatetrenone on prednisolone-induced bone loss in rats. Bone. 1993 Nov-Dec;14(6):813-8.

Ortoft G, Brüel A, Andreassen TT, Oxlund H. Growth hormone is not able to counteract osteopenia of rat cortical bone induced by glucocorticoid with protracted effect. Bone. 1995 Dec;17(6):543-48.

Hara K, Kobayashi M, Akiyama Y. Vitamin K2 (menatetrenone) inhibits bone loss induced by prednisolone partly through enhancement of bone formation in rats. Bone. 2002 Nov;31(5):575-81.

Goulding A, McIntosh J. Effects of NaCl on calcium balance, parathyroid function and hydroxyproline excretion in prednisolone-treated rats consuming low calcium diet. J Nutr. 1986 Jun;116(6):1037-44.

Schwartz Z, Shani J, Soskolne WA, Touma H, Amir D, Sela J. Uptake and biodistribution of technetium-99m-MD32P during rat tibial bone repair. J Nucl Med. 1993 Jan;34(1):104-8.

Delmas PD, Malaval L, Arlot ME, Meunier PJ. Serum bone Gla-protein compared to bone histomorphometry in endocrine diseases. Bone. 1985;6(5):339-41.

Peck WA, Brandt J, Miller I. Hydrocortisone-induced inhibition of protein synthesis and uridine incorporation in isolated bone cells in vitro. Proc Natl Acad Sci U S A. 1967 Jun;57(6):1599-606.

Nielsen HK, Thomsen K, Eriksen EF, Charles P, Storm T, Mosekilde L. The effects of high-dose glucocorticoid administration on serum bone gamma carboxyglutamic acid-containing protein, serum alkaline phosphatase and vitamin D metabolites in normal subjects. Bone Miner. 1988 Apr;4(1):105-13.

Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998 Jul 15;102(2):274-82.

Pereira RM, Delany AM, Canalis E. Cortisol inhibits the differentiation and apoptosis of osteoblasts in culture. Bone. 2001 May;28(5):484-90.

Delany AM, Durant D, Canalis E. Glucocorticoid suppression of IGF I transcription in osteoblasts. Mol Endcrinol. Mol Endocrinol. 2001 Oct;15(10):1781-9.

Hahn TJ, Halstead LR, Baran DT. Effects off short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man. J Clin Endocrinol Metab. 1981 Jan;52(1):111-5.

 Klein RG, Arnaud SB, Gallagher JC, Deluca HF, Riggs BL. Intestinal calcium absorption in exogenous hypercortisonism. Role of 25-hydroxyvitamin D and corticosteroid dose. J Clin Invest. 1977 Jul;60(1):253-9.

Hahn TJ, Halstead LR, Teitelbaum SL, Hahn BH. Altered mineral metabolism in glucocorticoid-induced osteopenia. Effect of 25-hydroxyvitamin D administration. J Clin Invest. 1979 Aug;64(2):655-65.

Reid IR. Glucocorticoid effects on bone. J Clin Endocrinol Metab. 1998 Jun;83(6):1860-2.

Suzuki Y, Ichikawa Y, Saito E, Homma M. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism. 1983 Feb;32(2):151-6.

Natsui K, Tanaka K, Suda M, Yasoda A, Sakuma Y, Ozasa A, Ozaki S, Nakao K. High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass. Osteoporos Int. 2006 Jan;17(1):105-8.

Moghadam-Kia S, Werth VP. Prevention and treatment of systemic glucocorticoid side effects.  Int J Dermatol. 2010 Mar;49(3):239-48.

Manolagas SC, Weinstein RS. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res. 1999 Jul;14(7):1061-6.

Holder LE, Schwarz C, Wernicke PG, Michael RH. Radionuclide bone imaging in the early detection of fractures of the proximal femur (hip): multifactorial analysis. Radiology. 1990 Feb;174(2):509-15.

Kanishi D. 99mTc-MDP accumulation mechanisms in bone. Oral Surg Oral Med Oral Pathol. 1993 Feb;75(2):239-46.